RxDoctor Payments Data

Alex David, MD

Nephrology · Little Rock, ARNPI 1437140373

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 93.0% of the total across 316 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by Amgen at 29.1% of the total.

$6,051in general payments, 2019–2025

Across 316 payments — averaging $19.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$2K
  • Fresenius USA Marketing, Inc.$517
  • Travere Therapeutics, Inc.$436
  • AstraZeneca$433
  • Mallinckrodt Hospital Products Inc.$421
  • Vifor Pharma, Inc.$363
  • plus $2K from 19 others

What the payments were for

  • Food & beverage$5,62993%
  • Education$4227%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,051 in reported general payments places this provider in the 85th percentile of 85 nephrology providers in Arkansas.

See all nephrology providers in Arkansas

Medicare billing

Part B allowed, 2024
$367,730
Medicare patients
800
Services billed
4,130

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol81$59,131
JardianceEmpagliflozin31$33,811
ProsolParenteral Amino Acid 20% No.1139$26,664
NulojixBelatacept11$21,452
KerendiaFinerenone17$13,402
LokelmaSodium Zirconium Cyclosilicate13$10,386
Sevelamer Carbonate52$10,339
AmbienZolpidem Tartrate12$7,608
EliquisApixaban12$6,773
Carvedilol ErCarvedilol Phosphate12$5,571
DapagliflozinDapagliflozin Propanediol14$4,632
Calcium Acetate48$2,168
Calcitriol88$2,054
Nifedipine ErNifedipine61$1,926
Hydralazine Hcl111$1,397

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$433$69,51894 claims
Boehringer IngelheimJardiance$48$33,81131 claims
BayerKerendia$215$13,40217 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 85 nephrology providers in Arkansas.

Other nephrology in Little Rock

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →